Merck's new PD-1 cancer drug Keytruda (pembrolizumab) has posted another round of positive early-stage results that help demonstrate its potential in an important cancer R&D arena: hematology. But some of the biggest players and punters in the immuno-oncology field may be left wondering if Merck's top therapeutic hopeful is losing market ground to Bristol-Myers Squibb's rival treatment.
India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.
Formed in 2011, Palo Alto, CA's Science Exchange is, as The Economist phrases it, the "Uber for experiments." The site recruits labs from around the world to list their available services and then invites researchers to browse for their ideal partner.
Ferrets are a particularly good model for many human lung diseases, not the least of which is influenza, which infects the animals and spreads among them much like it does in people. Now scientists who specialize in respiratory disorders have a new tool: a draft ferret genome created by an international team of researchers.
Researchers at Case Western Reserve University School of Medicine have taken an end-around approach to treating spinal cord injuries, crafting a treatment that has shown the promise of reversing paralysis in early studies.
Celgene will hold an investor event at the ASH conference on Dec. 7, which will doubtless provide further details on its own data and the advances of its partners.
Chris Viehbacher had planned to cut Sanofi's costs in France, in part by shuttering an R&D site in Toulouse. Now Sanofi plans to pay German company Evotec to take over the operations there.
Researchers at the University of Illinois at Urbana-Champaign have developed a hydrolyzable polymer that can be used as a drug delivery material.
Over the past few years, France's DBV Technologies has been financing its food allergy patch, and a new study showing that the patch helps children tolerate more peanuts has boosted the market value to the tune of $1 billion, according to a report from Bloomberg.
The National Institutes of Health recently awarded $20 million to a collaboration of researchers led by the Oak Crest Institute of Science to develop a novel intravaginal ring designed to prevent the spread of sexually transmitted HIV in women by delivering powerful combinations of antiretroviral drugs.